Disparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: A prognostic analysis based on real-world data comparing Brazil's public and private healthcare systems

This publication has 41 references indexed in Scilit:

• Global representativeness and impact of funding sources in cost-effectiveness research on systemic therapies for advanced breast cancer: A systematic review
  The Breast, 2024
• Analysis of Breast Cancer Mortality in the US—1975 to 2019
  JAMA, 2024
• Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival
  The Breast, 2023
• Prognostic Factors and Survival Outcomes of Patients With Early HER2+ Breast Cancer Treated With Trastuzumab in a Brazilian Public Reference Center: A Real-World Study
  Clinical Breast Cancer, 2023
• Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper
  Clinical Breast Cancer, 2023
• The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)
  Breast Cancer Research and Treatment, 2020
• Use of Real-world Data for New Drug Applications and Line Extensions
  Clinical Therapeutics, 2020
• Trial designs using real‐world data: The changing landscape of the regulatory approval process
  Pharmacoepidemiology and Drug Safety, 2019
• Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
  European Journal of Cancer, 2018
• The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer
  Clinical Breast Cancer, 2018